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AcetylcholinesteraseAbstract Background: Alzheimer’s disease (AD), the most common cause of progressive demen-
tia in the elderly population, is a chronic neurodegenerative disorder that leads to disturbances of
cognitive functions. Although the primary cause of AD remains unclear, brain acetylcholine deﬁ-
ciency and oxidative stress are principal pathogenic factors.
Aim of the study: The present study was constructed to investigate the anti-amnestic effect of
naringenin on scopolamine-induced behavioral and neurochemical changes in rats.
Methods: Naringenin (50 and 100 mg/kg) and donepezil (2.5 mg/kg) were orally administered for 7
successive days. Dementia was induced at the end of the treatment period by a single injection of
scopolamine (20 mg/kg; i.p.). Conditioned avoidance and Y-maze tests were conducted 30 min
thereafter then rats were sacriﬁced and brain homogenates were used for the estimation of nor-
adrenaline, dopamine, serotonin and c-amino butyric acid contents along with acetylcholinesterase
activity. In addition, certain inﬂammatory and oxidative stress markers as well as histopathologic
studies were performed.
Results: Scopolamine resulted in memory impairment that was coupled by alterations in the esti-
mated neurotransmitters and acetylcholinesterase activity as well as increased brain oxidative stress.
Pretreatment of rats with naringenin in both doses mitigated scopolamine-induced behavioral, neu-
rochemical and histological changes in a manner comparable to donepezil.
Conclusions: The observed anti-amnestic effect of naringenin makes it a promising candidate for
clinical trials in patients with cognitive impairment.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Alzheimer’s disease (AD), the most common form of senile
dementia, is characterized by memory loss accompanied by
degeneration of basal forebrain cortical cholinergic neurons.1,2
The pathogenesis of AD is multifactorial and includes
degeneration of cholinergic neurons, abnormal phosphoryla-
tion of the protein tau, oxidative stress, and altered protein
processing resulting in abnormal b-amyloid peptide (Ab)
accumulation.1–3
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humans and also impairs learning in animals.4 Hence, it is
widely utilized as a model simulating human dementia in gen-
eral and AD in particular.5,6
Treatment of dementia of Alzheimer type is usually done
using acetylcholinesterase (AchE) inhibitors as donepezil and
memantine, an N-methyl-D-aspartate receptor antagonist.1,7
The present therapies produce modest symptomatic improve-
ments in patients; hence, searching for alternative or adjuvant
anti-amnestic therapies is mandatory.
Naringenin is a ﬂavanone found abundantly in citrus fruits.
It possesses a plethora of pharmacological effects including
antioxidant,8,9 anti-inﬂammatory,10,11 immune-modula-
tory12,13 and neuroprotective properties14,15 as well as peroxi-
some proliferator-activated receptor activation16 and nuclear
factor-kappaB (NF-jB) inhibition.15
Accordingly, the present study was performed to investi-
gate the possible modulatory effect of naringenin on scopol-
amine-induced dementia and to compare such effects with
donepezil, a commonly used agent in dementia and AD.
The study design included evaluating effects of naringenin
on some of the underlying mechanisms involved in AD
progression.
2. Materials and methods
2.1. Animals
Adult male albino Wistar rats, weighing 150–200 g each, were
used in the present study. Animals were allocated in groups
and were allowed to accommodate for one week in the animal
house at Faculty of Pharmacy, Cairo University, before
subjecting them to experimentation. They were provided with
a standard pellet diet and were given water ad libitum. The ani-
mals were kept at a temperature of 22 ± 3 C and a 12 h light/
dark cycle as well as a constant relative humidity throughout
the experimental period. The study was approved by the Ethics
Committee for Animal Experimentation at Faculty of Phar-
macy, Cairo University, Egypt.
2.2. Drugs and chemicals
Scopolamine hydrobromide was purchased from Sigma–Aldrich
(MO, USA). It was dissolved in saline and i.p. administered in
a dose of 20 mg/kg.17 Donepezil hydrochloride was purchased
from Pﬁzer (Cairo, Egypt). It was dissolved in saline and
administered p.o. in a dose of 2.5 mg/kg.18 Naringenin was
purchased from Sigma–Aldrich (MO, USA). It was suspended
in 1% Tween 80 and administered p.o. in doses of 50 and
100 mg/kg.19 Reagent kits for tumor necrosis factor-alpha
(TNF-a) and AchE were purchased from R&D Systems
(MN, USA) and Quimica Clinica Aplicada (S.A., Spain),
respectively.
2.3. Experimental design
Animals were classiﬁed into ﬁve groups (10 rats each). Treat-
ments were given p.o. for seven successive days. One hour
after the last dose of test agents, all animals were i.p. injected
with scopolamine hydrobromide (20 mg/kg) except the ﬁrstgroup (control group). Animals were treated according to
the following scheme: groups I and II received 1% Tween
80; meanwhile groups III and IV received donepezil
hydrochloride (2.5 mg/kg) or naringenin (50 and 100 mg/
kg), respectively. Conditioned avoidance and Y-maze
spontaneous alternation tests were conducted 30 min after
scopolamine injection. Immediately after performing the
behavioral tests, rats were sacriﬁced by decapitation, brains
were rapidly isolated. Each brain was dissected through the
midline into two hemispheres. Each hemisphere was weighed.
One of the two hemispheres was homogenized in ice-cold
acidiﬁed butanol to obtain 10% homogenate that was
used for the determination of brain dopamine (DA),
norepinephrine (NE) and serotonin (5-HT) contents. The
other hemisphere was homogenized in ice-cold 50 mM
phosphate buffer (pH 7.4) to prepare 10% homogenate that
was used for the estimation of gamma aminobutyric acid
(GABA), lipid peroxides, reduced glutathione (GSH), nitric
oxide (NO) and TNF-a contents as well as AchE
activity. Finally, brains of 2–3 rats from each group were
preserved in 10% formalin and kept for histopathologic
examination.
2.4. Conditioned avoidance test
The test was carried out using a shuttle box (Reﬂex-16, Colum-
bus Instruments, USA) as described by Hinrichs et al.20 The
shuttle box consisted of two grid ﬂoor compartments
(29 · 29 · 26 cm) separated by a non-transparent partition
with a single opening (8 · 4.5 cm). Light (12 W) attached to
the ceiling of the shuttle box was used as conditioned stimuli;
whereas, the unconditioned stimulus was a foot shock
(0.8 mA) delivered through the metallic grid ﬂoor. Rats were
trained for three days prior to conduction of the experiment
by subjecting them to the conditioned stimulus (light) followed
by the unconditioned one (electric shock). After injection of
scopolamine, each rat was placed in the shuttle box and al-
lowed to adapt for 3 min. Following adaptation, the condi-
tioned stimulus was presented for 10 s prior to the
unconditioned stimulus. If the rat crossed to the opposite com-
partment during 10 s of conditioned stimulus, the electric
shock was avoided, otherwise failure of avoidance was
recorded.
2.5. Y-maze spontaneous alternation test
The Y-maze test was performed as described by Wall and
Messier.21 The maze was made of 3 identical arms, 40 cm long,
35 cm high and 12 cm wide, positioned at equal angles and la-
beled A, B, and C. Rats were placed at the end of one arm and
allowed to move freely through the maze during a 5 min ses-
sion. Spontaneous alternation was examined by visually
recording the pattern of entrance into each arm in the maze
for each rat. Arm entry was considered to be complete when
the hind paws of the rat were completely placed in the arm.
Alternation was deﬁned as successive entries into the three
arms on overlapping triplet set (i.e., ABC, BCA. . ...). Accord-
ingly, the spontaneous alternation performance (SAP) score,
spontaneous alternation percentage (SAP %) and total arm
entries (TAE) were calculated.
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contents
Determinations of brain DA, NE and 5-HT contents were car-
ried out according to themethod described byCiarlone22 and ex-
pressed as lg/gwet tissue. Themethod is based on a ﬂuorometric
assay in which a ﬂuorescent product results from the reaction
with a mixture of alkaline sulﬁte and iodine solution (in case
of DA and NE) and the reaction with ortho-phthalaldehyde
solution (in case of 5-HT). The ﬂuorescence of DA was read at
excitation 320 nm and emission 375 nm; whereas that of NE
was read at excitation 380 nm and emission 480 nm. Regarding
5-HT, its ﬂuorescence was read at excitation 355 nm and
emission 470 nm using Shimadzu spectrophotoﬂuorometer
(RF-510, Japan). The results were expressed as lg/g wet tissue.
2.7. Estimation of brain lipid peroxides content
Lipid peroxides were estimated as thiobarbituric acid reactive
substances (TBARS) using malondialdehyde (MDA) as a stan-
dard according to the thiobarbituric acid reaction of Mihara
and Uchiyama.23 To brain homogenates, orthophosphoric
acid (1%) and thiobarbituric acid (0.6%) were added, mixtures
were boiled for 45 min at 100 C, then cooled. The colored
product was extracted by n-butanol. The absorbance of the or-
ganic layer was read at 535 and 520 nm and the difference in
absorbance was calculated as lipid peroxides level expressed
as TBARS (nmol/g wet tissue).
2.8. Estimation of brain reduced glutathione content
The method for the assessment of GSH (mg/g wet tissue) in the
brain homogenates was based on that of Beutler et al.24 Homog-
enates were deproteinized with 5-sulfuosalicylic acid (10%) for
30 min at 4 C then centrifuged at 3000g for 15 min at 4 C.
An aliquot of the acid soluble supernatant was diluted with
phosphate buffer (0.3 M, pH= 7.7) and 5,50-dithiobis-2-nitro-
benzoic acid (1 mM) was added to the samples. The optical den-
sity of the produced colored product was determined at 412 nm.
2.9. Estimation of brain nitric oxide content
NO in brain homogenates was determined as total nitrate/ni-
trite (NOx) using Griess reagent,
25 after reduction of nitrate
to nitrite by vanadium trichloride, and expressed as lmol/g
wet tissue. Griess reaction entails formation of a chromophore
from the diazotization of sulfanilamide by acidic nitrite fol-
lowed by coupling with N-(1-naphthyl) ethylenediamine to
form a colored azo derivative that can be measured spectro-
photometrically at 540 nm.
2.10. Estimation of brain GABA content
Determination of brain GABA content was carried out
according to the method described by Sutton and Simmonds.26
The method depends on the formation of a ﬂuorescent product
from the reaction between GABA and ninhydrin at alkaline
pH in the presence of glutamate. The resultant ﬂuorescence
is read at wavelengths of 380 nm for excitation and 450 nm
for emission using Shimadzu spectrophotoﬂuorometer(RF-510, Japan) and the concentration of GABA was ex-
pressed as lg/g wet tissue.
2.11. Estimation of brain content of tumor necrosis factor-alpha
and acetylcholinesterase activity
Brain TNF-a content was assessed using ELISA kits and the
results were expressed as pg/g wet tissue. AchE activity (U/g
wet tissue) was measured according to the method of den
Blaauwen et al.27 using a colorimetric reagent kit. All the
procedures of the used kits were performed following the
manufacturer’s instruction manual.
2.12. Histopathologic examination of brain tissues
Histopathologic assessment was performed on the brains of
2–3 rats randomly selected from each group. Brains were
immediately ﬁxed in 10% phosphate buffered formaldehyde,
embedded in parafﬁn, and 5 lm longitudinal sections were
performed. The sections were stained with hematoxylin and
eosin (H&E) and examined microscopically.
2.13. Statistical analysis
Data were expressed as means ± S.E.M., and comparisons be-
tween means were carried out using one way analysis of vari-
ance (ANOVA) followed by Tukey–Kramer multiple
comparisons test. Results of the behavioral experiments were
analyzed using Kruskal–Wallis non-parametric one way ANO-
VA followed by Dunn’s multiple comparisons test. A probabil-
ity level of less than 0.05 was accepted as being signiﬁcant in all
types of statistical tests.
3. Results
Scopolamine-induced dementia signiﬁcantly reduced the con-
ditioned avoidance response (CAR) by 32.32% and increased
unconditioned avoidance response (UAR) by 3.3-folds as com-
pared to the normal group. Pretreatment with donepezil signif-
icantly increased CAR by 32.51% and decreased UAR by
53.82%; meanwhile, naringenin (50 mg/kg) increased CAR
by 38.98% and decreased UAR by 66.80% when compared
to scopolamine control group (Table 1).
In Y-Maize test, scopolamine signiﬁcantly decreased SAP
% by 37.12% as compared to the normal control group. Pre-
treatment of rats with donepezil or naringenin (50 mg/kg) in-
creased SAP % by 59.69% and 54.41%, respectively as
compared to scopolamine control group (Table 2).
Scopolamine administration increased brain AchE activity
by 73.72% as compared with the normal control group.
Administration of donepezil or naringenin (50 and 100 mg/
kg) decreased scopolamine-induced elevation in AchE activity
by 44.44%, 49.10% and 34.24%, respectively as compared to
scopolamine control group (Fig. 1A).
In the same context, scopolamine reduced brain GABA
content by 21.1% as compared to the normal control group.
Treatment with donepezil increased GABA content by
27.27% as compared to scopolamine control group. On the
other hand, administration of naringenin did not prevent sco-
polamine-induced reduction in brain GABA content (Fig. 1B).
Table 2 Effect of naringenin on Y-maze behavioral test in scopolamine-induced demented rats.
Groups Parameters
SAP % TAE SAP
Control (1% Tween 80) 28.88 ± 0.66 16.67 ± 2.30 4.63 ± 0.68
Scopolamine (20 mg/kg) 18.16 ± 1.45* 15.27 ± 1.66 2.64 ± 0.51
Donepezil (2.5 mg/kg) 29.00 ± 1.56@ 14.33 ± 1.54 3.33 ± 0.42
Naringenin (50 mg/kg) 28.04 ± 1.78@ 18.00 ± 4.97 5.00 ± 0.71
Naringenin (100 mg/kg) 24.82 ± 1.61 15.50 ± 5.25 3.50 ± 1.61
Donepezil and naringenin were orally administered for 7 successive days. Dementia was induced on the 7th day by single i.p. injection of
scopolamine 1 h after the last dose of test agents. Y-maze behavioral test was performed 1 h after scopolamine injection. Total arm entries
(TAE) and spontaneous alternation performance (SAP) were measured during 5-min session and % SAP was calculated.
Data are expressed as mean ± S.E.M of 8 animals. Statistical analysis was carried out by non-parametric One-Way ANOVA followed by
Dunn’s multiple comparisons test.
* p< 0.05 vs. control.
@ p< 0.05 vs. scopolamine.
Table 1 Effect of naringenin on the active avoidance learning in scopolamine-induced demented rats.
Groups Parameters
% CAR % UAR
Control (1% Tween 80) 91.43 ± 2.10 10.00 ± 1.83
Scopolamine (20 mg/kg) 61.88 ± 3.65* 33.13 ± 2.49*
Donepezil (2.5 mg/kg) 82.00 ± 4.64@ 15.30 ± 3.28@
Naringenin (50 mg/kg) 86.00 ± 3.67@ 11.00 ± 2.45@
Naringenin (100 mg/kg) 70.00 ± 3.54* 23.75 ± 4.73*
Donepezil and naringenin were orally administered for 7 successive days. Dementia was induced on the 7th day by single i.p. injection of
scopolamine 1 h after the last dose of test agents. Conditioned avoidance test was performed 30 min after scopolamine injection in trained rats.
Each value represents the mean percentage of conditioned (CAR) and unconditioned (UAR) avoidances for each group (8 rats) ± S.E.
Statistical analysis was carried out by non-parametric One-Way ANOVA followed by Dunn’s multiple comparisons test.
* p< 0.05 vs. control.
@ p< 0.05 vs. scopolamine.
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brain contents of 5-HT, NA and DA by 38.56%, 33.75%
and 32.98%, respectively as compared with the normal group.
Donepezil decreased the elevated 5-HT, NE and DA brain
contents by 16.04%, 36.16% and 23.98%, respectively as com-
pared with scopolamine control group (Fig. 2A–C). Likewise,
pretreatment of rats with naringenin (50 mg/kg) caused a sig-
niﬁcant decrease in the elevated brain 5-HT and NE contents
by 33.02% and 22.43%, respectively as compared to that of
scopolamine control animals; meanwhile, naringenin
(100 mg/kg) signiﬁcantly decreased the elevated 5-HT and
NE brain contents by 34.43% and 28.97%, respectively as
compared with scopolamine control group (Fig. 2A and B).
In the present study, administration of scopolamine signif-
icantly increased brain TBARS content by 43.80% as com-
pared to that of the normal group. Donepezil reduced
scopolamine-induced elevation of TBARS by 22.81% as com-
pared to scopolamine control group; meanwhile, pretreatment
with naringenin (50 and 100 mg/kg) normalized the elevated
TBARS content as compared with scopolamine control group
(Fig. 3A).
Scopolamine-induced dementia resulted in decreased brain
GSH content by 43.94% as compared to the normal
group. Pretreatment with donepezil or naringenin (50 and
100 mg/kg) increased brain GSH content by 47.25%, 78.00%
and 97.80%, respectively as compared to scopolamine control
group (Fig. 3B).In addition, scopolamine resulted in signiﬁcant elevation in
brain NOx content by 44.8% as compared to the control
group. Donepezil signiﬁcantly decreased the elevated brain
NOx content by 38.98%; meanwhile naringenin in both dose
levels used normalized the elevated NOx content as compared
to scopolamine control group (Fig. 4A).
In the current study, scopolamine-induced dementia was
not associated with changes in brain content of TNF-a when
compared to the normal group; however, pretreatment of rats
with naringenin (50 and 100 mg/kg) signiﬁcantly elevated the
brain content of TNF-a by 26.77- and 19.85-folds, respectively
as compared to scopolamine control group (Fig. 4B).
Examination of brain sections of control rats showed the
normal structure of the cerebral cortex and hippocampus
(Fig. 5A). On the other hand, brain sections of scopolamine-
induced demented rats revealed severe congestion in the blood
capillaries with perivascular edema in the cortex; meanwhile,
the hippocampus showed encephalomalacia and edema in
the tissue matrix with demyelination and neuronal degenera-
tion (Fig. 5B).
Brains of rats pretreated with donepezil showed diffuse gli-
osis all over the cerebral cortex coupled by some pathological
changes in the hippocampus in the form of shrinkage and
swelling of some neuronal cells with vacuolation of cytoplasm
(Fig. 5C).
Brain sections of rats pretreated with naringenin (50 mg/kg)
revealed focal gliosis in the cerebral cortex and pyramidal cells
Figure 1 Effect of naringenin (NAR) on brain: (A) cholinesterase (AchE) activity and (B) c-aminobutyric acid (GABA) content in
scopolamine-induced demented rats. Donepezil (2.5 mg/kg) and NAR (50 and 100 mg/kg) were orally administered for 7 successive days.
Dementia was induced on the 7th day by single i.p. injection of scopolamine (20 mg/kg) 1 h after the last dose of test agents. Each bar with
vertical line represents the mean of 8 rats ± S.E. Statistical analysis was carried out using One-Way ANOVA followed by Tukey Kramer’s
multiple comparisons test; *p< 0.05 vs. control, @p < 0.05 vs. scopolamine; bp< 0.05 vs. donepezil.
Naringenin protects against scopolamine-induced dementia in rats 19in the hippocampus separated from each other with irregular
outline (Fig. 5D). Brain sections of rats pretreated with
naringenin (100 mg/kg) showed the normal histological struc-
ture of the cerebral cortex; however, the hippocampus showed
shrinkage in some pyramidal cells and vacuolated cytoplasm
(Fig. 5E).
4. Discussion
Scopolamine-induced dementia has been used extensively to
evaluate potential therapeutic agents for treating AD.5,6
Scopolamine inﬂuences the expression of several genes associ-
ated with muscarinic receptor signaling pathways, apoptosis,
and cell differentiation in rat brain.28 Hence, it causes
profound memory impairment in animals and humans asdegeneration and dysfunction of the cortical cholinergic neu-
rons is closely associated with cognitive deﬁcits in AD.29
Indeed in the current study, single i.p. injection of
scopolamine was coupled by signiﬁcant decrease in CAR in
conditioned avoidance test and decreased SAP % of rats in
Y-maze test coupled with increased brain AchE activity and
marked histopathologic changes in the brain. Scopolamine-in-
duced behavioral, neurochemical and histological changes
were attenuated by pretreatment of rats with donepezil and
naringenin. Similar results regarding the effects of scopol-
amine,30–32 donepezil30,31 and naringenin19,33 were reported.
The loss of cholinergic innervation correlates well with the
degree of dementia and the severity of the neuropathologic
hallmarks of AD.29 Therefore, naringenin through its inhibi-
tory effect on AChE activity as observed in the present study
Figure 2 Effect of naringenin (NAR) on brain contents of: (A) serotonin (5-HT), (B) norepinephrine (NE) and (C) dopamine (DA) in
scopolamine-induced demented rats. Donepezil (2.5 mg/kg) and NAR (50 and 100 mg/kg) were orally administered for 7 successive days.
Dementia was induced on the 7th day by single i.p. injection of scopolamine (20 mg/kg) 1 h after the last dose of test agents. Each bar with
vertical line represents the mean of 8 rats ± S.E. Statistical analysis was carried out using One-Way ANOVA followed by Tukey Kramer’s
multiple comparisons test; *p< 0.05 vs. control, @p < 0.05 vs. scopolamine; bp< 0.05 vs. donepezil.
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served anti-amnestic effects.
In the current experiments, scopolamine-induced patholog-
ical and behavioral changes were coupled by increased brain
DA, NE and 5-HT contents that were prevented by pretreat-
ment with donepezil; whereas naringenin protected against
changes induced in NE and 5-HT but not DA. In a previous
study, scopolamine ability to decrease DA turnover in hippo-
campus and frontal cortex parallel to its induced amnesic ef-
fects, measured by passive avoidance test, was reported.34
Moreover, scopolamine-induced deﬁcit in the radial-arm maze
was counteracted by DA receptor blockers.35
Several lines of evidence from animal and clinical studies
have also indicated the role of 5-HT and its receptors in differ-
ent aspects of cognitive dysfunction. Yasuno et al.36 demon-
strated a dose-dependent decline in explicit verbal memory of
healthy volunteers by administration of tandospirone, a
5-HT1A partial agonist. Indeed increased 5-HT1A receptor
density correlated with the cognitive impairment observed in
AD and provided the basis for the use of 5-HT1A antagonists
in AD treatment.37 Regarding NE, Szot and his colleagues
demonstrated a signiﬁcant increase in mRNA expression ofthe rate limiting enzyme for NE synthesis, tyrosine hydroxy-
lase, in the locus ceruleus of AD subjects.38
The ability of naringenin and donepezil to ameliorate sco-
polamine-induced changes in brain neurotransmitters could
be attributed to their observed effects on attenuating increased
brain AchE activity and oxidative stress markers, the impor-
tant hallmarks in dementia pathology.29,39
Scopolamine-induced dementia, in the present study, was
coupled by reduced brain GABA content, an effect that was
prevented by donepezil but not naringenin. Dysfunction of
the GABAergic system is known to contribute in cognitive
impairment in humans and the lower brain GABA content
in patients with AD was reported.40,41 Anderson et al.42 re-
ported that naringenin does not act as anxiolytic by modula-
tion of the GABA-A receptor, which could explain the lack
of naringenin effects on GABA brain content, in the present
study.
Brain damage due to oxidative stress can induce impair-
ment in learning and memory abilities.39 In the same context,
several investigators reported that scopolamine-induced
amnesia and memory impairment in rats were associated with
elevated brain lipid peroxides and reduced brain stores of
Figure 3 Effect of naringenin (NAR) on brain contents of: (A) thiobarbituric acid reactive substances (TBARS) and (B) reduced
glutathione (GSH) in scopolamine-induced demented rats. Donepezil (2.5 mg/kg) and NAR (50 and 100 mg/kg) were orally administered
for 7 successive days. Dementia was induced on the 7th day by single i.p. injection of scopolamine (20 mg/kg) 1 h after the last dose of test
agents. Each bar with vertical line represents the mean of 8 rats ± S.E. Statistical analysis was carried out using One-Way ANOVA
followed by Tukey Kramer’s multiple comparisons test; *p< 0.05 vs. control, @p < 0.05 vs. scopolamine; bp< 0.05 vs. donepezil.
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ments by increased brain lipid peroxidation parallel to reduced
GSH stores by scopolamine.
The observed neuroprotective effect of naringenin or
donepezil in the present study was paralleled by decreased
brain lipid peroxidation and increased GSH stores. Naringenin
antioxidant properties have been previously reported.8,9
Naringenin can chelate ferrous ions and decrease the forma-
tion of hydroxyl radical via inhibition of iron-dependent
Fenton reaction.46 The antioxidant properties of naringenin
reside in the presence of 40-hydroxyl group in its structure
which possesses electron donating properties thereby protect-
ing membranes from the free radical attack.47In the present study, scopolamine-induced dementia was
associated by increased brain NO that was prevented by
donepezil and naringenin. AD lesions were reported to display
several hallmarks of oxidative and nitrosative injury, including
nitration of protein tyrosine residues which indicates the vici-
nal production of peroxynitrite from NO and superoxide
anion.48,49
Raza et al.15 demonstrated the ability of naringenin to
reduce brain NO content in an experimental model of stroke
by suppressing NF-jB-mediated neuroinﬂammation. Suppres-
sion of iNOS expression by naringenin was also reported in
different models of inﬂammation.10,11 Hence, we can assume
that naringenin may exert part of its observed neuroprotective
Figure 4 Effect of naringenin (NAR) on brain contents of: (A) total nitrate/nitrite (NOx) and (B) tumor necrosis factor-alpha (TNF-a)
in scopolamine-induced demented rats. Donepezil (2.5 mg/kg) and naringenin (50 and 100 mg/kg) were orally administered for 7
successive days. Dementia was induced on the 7th day by single i.p. injection of scopolamine (20 mg/kg) 1 h after the last dose of test
agents. Each bar with vertical line represents the mean of 8 rats ± S.E. Statistical analysis was carried out using One-Way ANOVA
followed by Tukey Kramer’s multiple comparisons test; *p< 0.05 vs. control, @p < 0.05 vs. scopolamine; bp< 0.05 vs. donepezil.
22 H.F. Zaki et al.effect by its anti-inﬂammatory properties based on the strong
link between inﬂammation and AD pathophysiology.7
Scopolamine-induced dementia was not coupled by changes
in brain TNF-a; meanwhile naringenin in both dose levels
markedly increased brain content of TNF-a. The dual role
played by TNF-a in brain pathology was previously reviewed
revealing signiﬁcant beneﬁcial effects predominantly mediated
by TNFR2 receptor; whereas TNFR1 promotes neurotoxicity
both directly and indirectly.50,51 In the same context, several
investigators reported a neuroprotective effect of TNF-a in
certain brain insults.52,53 Hence the effect of naringenin on
brain content of TNF-a could be regarded as part of its neuro-
protective theme that was apparent by cognitive enhancement,reduced oxidative and nitrosative stress as well as reduced
brain AchE activity. Naringenin may also increase brain con-
tent of TNF-a by virtue of its immune-modulating proper-
ties12,13 owing to the important role of TNF-a and
inﬂammation in the immune response.
In conclusion, the prevalence of AD and dementia has in-
creased signiﬁcantly nowadays. As none of the available medi-
cations appears to be able to stop the disease progression, there
is enormous medical need for the development of novel
therapeutic strategies that target the underlying pathogenic
mechanisms in AD. Keeping in mind that naringenin has broad
cytoprotective properties as observed in the current study; its
use might slow the progression of the multifactorial AD.
Figure 5 Photomicrograph of brain sections of: (A) control rat showing the normal histological structure of the meninges (m), cerebral
cortex (c) and hippocampus (hp); (B) scopolamine-induced demented rat showing severe congestion in the blood capillaries with
perivascular edema (arrow) in the cerebral cortex together with edema and encephalomalacia in the hippocampus (d); (C) scopolamine-
induced demented rat treated with donepezil showing diffuse gliosis in the cerebral cortex and shrinkage with pyknotic nuclei in some
pyramidal cells in the hippocampus; (D) scopolamine-induced demented rat treated with naringenin (50 mg/kg) showing focal gliosis (g) in
the cerebral cortex and pyramidal cells in the hippocampus separated away from each other with irregular outline; (E) scopolamine-
induced demented rat treated with naringenin (100 mg/kg) showing the normal histologic structure of the cerebral cortex in addition to
shrinkage with pyknotic nuclei in some pyramidal cells and vacuolated cytoplasm in the hippocampus. (H&E · 40, 60, 150, 600).
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